MedTrace Logo

Pyridostigmine and Its Effects on Autonomic Modulation in Diabetic Patients

NCT00953914 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2011-07-07

No results posted yet for this study

Summary

The purpose of the study is to determine if pyridostigmine bromide improves heart rate variability of type 2 diabetes mellitus subjects with cardiovascular autonomic neuropathy.

Conditions

  • Diabetes Complications

Interventions

DRUG

Pyridostigmine

Pills containing 30 mg of Pyridostigmine will be orally administered 3 times daily for 1 day.

DRUG

Placebo

If subject is randomized to placebo, placebo pills will give 30 mg orally 3 times daily for 2 days

Sponsors & Collaborators

  • Hospital de Clinicas de Porto Alegre

    lead OTHER

Principal Investigators

  • Ruy S. Moraes, MD, Phd · Hospital de Clínicas de Porto Alegre

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-03-31
Primary Completion
2009-07-31
Completion
2010-05-31

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00953914 on ClinicalTrials.gov